What 8 Analyst Ratings Have To Say About Genmab
Portfolio Pulse from Benzinga Insights
Eight analysts have provided ratings for Genmab (NASDAQ: GMAB) over the past quarter, with all ratings being bullish. The average 12-month price target is $50.0, reflecting a slight increase from the previous target. Genmab has shown strong financial performance with significant revenue growth, high net margins, and effective debt management.
August 01, 2024 | 7:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eight analysts have rated Genmab (NASDAQ: GMAB) as bullish over the past quarter. The average 12-month price target is $50.0, indicating a slight increase from the previous target. Genmab's financial performance is strong, with notable revenue growth, high net margins, and effective debt management.
All eight analysts have given bullish ratings for Genmab, reflecting positive sentiment. The average price target has increased slightly, indicating optimism about future performance. Genmab's strong financial metrics, including significant revenue growth and high net margins, support this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100